alexa Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of terbium-149.
Social & Political Sciences

Social & Political Sciences


Author(s): Allen BJ, Blagojevic N

Abstract Share this page

Abstract The efficacy of systemic cancer therapy rests on the ability of a toxin to be preferentially located in cancer cells, so that cancer cell kill is maximized and normal tissue spared. This requires that the lifetime of the toxin be less than the lifetime of the carrier in the body, effectively ruling out chemical toxins, as they remain effective until excreted from the body. The requirement of localization of dose to the cancer cell makes radioactive beta-emitting radionuclides unattractive. Alpha-emitting radionuclides are much more appropriate toxins, as their efficacy depends on the high energy and short range of the alpha particles, and terbium-149 is shown to be the most efficacious of these. However, the merit of various alpha- and beta-emitting radionuclides depends on the stage and type of cancer. Recommendations are made with respect to the matching of the target cancer with required properties of the radiolabel and carrier.
This article was published in Nucl Med Commun and referenced in Anthropology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • World conference on Ecology and Ecosystems
    September 11-13, 2017 San Antonio, USA
  • 6th International Conference on Forensic Research & Technology
    Sep 18-20, 2017 Houston, USA
  • 2nd World Congress on Health and Medical Sociology
    September 25-26, 2017 Atlanta, Georgia, USA
  • 2nd Experts Meeting on Forensic Psychology and Criminology
    October 02-03, 2017 London, UK

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version